Monitor for a subsequent Form 4 or updated Form 144 to confirm whether the sale was executed. Given the small share quantity and institutional seller, this is a low-impact event unlikely to move the stock materially.
DYN drugs
DYN drug pipeline →- ▲ z-rostudirsen 8/10 Filed (BLA under FDA Priority Review); Phase 3 confirmatory trial (FORZETTO) ongoing · PDUFA date Jan 21, 2027
- ◆ z-basivarsen 7/10 Phase 3 (HARMONIA confirmatory trial, initiated March 2026); Phase 1/2 registrational cohort (ACHIEVE) fully enrolled · BLA filing Q3 2027
- ● DYNE-302 2/10
- All DYN drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 21 $19.21entry
- T+1 · 7mo ago +2.39%α +1.38% · $19.67
- T+5 · 7mo ago −5.47%α −6.55% · $18.16
- T+20 · 6mo ago −13.90%α −18.81% · $16.54
- T+60 · 4mo ago +18.27%α +11.37% · $22.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Atlas Venture Associates XI, L.P., a shareholder of Dyne Therapeutics, filed a Form 144 notifying intent to sell up to 1,401 shares of common stock. The filing is a routine notice of potential sale and does not confirm the transaction has occurred.
Key Facts
- Reporting entity: Atlas Venture Associates XI, L.P.
- Subject company: Dyne Therapeutics, Inc. (DYN)
- Security type: Common stock
- Number of shares proposed for sale: 1,401
- Filing date: April 20, 2026
- Method of sale: Not specified
- Shares acquired via private placement on April 26, 2019
Financial Impact
Approximately $285,944 (based on 1,401 shares at ~$204/share, derived from $3.4B market cap and ~16.5M shares outstanding)
Risk Factors
- Potential perception of negative sentiment if multiple insiders file near-simultaneous 144s
- Execution of sale could contribute to near-term supply pressure, though minimal given size
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001628280-26-026021 |
| Document: 0001628280-26-026021-index.html | 0001628280-26-026021 |
| Document: 0001628280-26-026021.txt | 0001628280-26-026021 |
Track record
54 reports on DYN
12 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 15 of 16 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
- Nov 5, 202611d ago 8-K Neutral 5/10 No price data
- Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
- Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
- Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
- Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
- Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers